EAM
TGTX icon

Exome Asset Management’s TG Therapeutics TGTX Stock Holding History

Exome Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-207,627
Closed -$4.86M – 79
2024
Q3 		$4.86M Sell
207,627
-43,973
-17% -$960K 3.28% 5
2024
Q2 		$4.48M Buy
251,600
+21,300
+9% +$340K 3.99% 4
2024
Q1 		$3.5M Buy
230,300
+27,000
+13% +$430K 3% 6
2023
Q4 		$3.47M Buy
+203,300
New +$2.36M 3.43% 6

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Exome Asset Management's TGTX Position: Q4 2024 in Review

Exome Asset Management sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 207,627 shares — an estimated $4.86M sold.

Exome Asset Management first reported a position in TGTX in Q4 2023 and held it in 4 quarters. The position peaked at $4.86M in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Exome Asset Management reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Exome Asset Management sold 207,627 TG Therapeutics shares in Q4 2024, an estimated $4.86M.
  • Exome Asset Management first reported a position in TG Therapeutics in Q4 2023 and held it in 4 quarters.
  • Exome Asset Management's TG Therapeutics position peaked at $4.86M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Exome Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.